Literature DB >> 14561084

Development of potent inhibitors of botulinum neurotoxin type B.

Christine Anne1, Serge Turcaud, Jean Quancard, Franck Teffo, Hervé Meudal, Marie-Claude Fournié-Zaluski, Bernard P Roques.   

Abstract

Botulinum neurotoxins are the most potent toxins known to date. They are zinc-metalloproteases able to cleave selectively an essential component of neurotransmitter exocytosis, causing the syndrome of botulism characterized by a flaccid paralysis. There is a great interest in designing antagonists of the action of these toxins. One way is to inhibit their catalytic activity. In this study, we report the design of such inhibitors directed toward BoNT/B. A study of the S(1) subsite specificity, using several beta-amino thiols, has shown that this subsite prefers a p-carboxybenzyl moiety. The specificity of the S(1)' and S(2)' subsites was studied using two libraries of pseudotripeptides containing the S(1) synthon derived from the best beta-amino thiol tested. Finally, a selection of various non natural amino acids for the recognition of the "prime" domain led to the most potent inhibitor of BoNT/B described to date with a K(i) value of 20 nM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561084     DOI: 10.1021/jm0300680

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.

Authors:  Rakhi Agarwal; Subramanyam Swaminathan
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

2.  A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Authors:  Nicholas T Salzameda; Lisa M Eubanks; Joseph S Zakhari; Kyoji Tsuchikama; Nicholas J DeNunzio; Karen N Allen; Mark S Hixon; Kim D Janda
Journal:  Chem Commun (Camb)       Date:  2011-01-04       Impact factor: 6.222

Review 3.  Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins.

Authors:  Katerina Capková; Nicholas T Salzameda; Kim D Janda
Journal:  Toxicon       Date:  2009-03-25       Impact factor: 3.033

4.  Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors.

Authors:  Nicholas T Salzameda; Joseph T Barbieri; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2009-08-27       Impact factor: 2.823

Review 5.  Botulinum neurotoxins and botulism: a novel therapeutic approach.

Authors:  Jeeraphong Thanongsaksrikul; Wanpen Chaicumpa
Journal:  Toxins (Basel)       Date:  2011-05-13       Impact factor: 4.546

Review 6.  The evolving field of biodefence: therapeutic developments and diagnostics.

Authors:  James C Burnett; Erik A Henchal; Alan L Schmaljohn; Sina Bavari
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

7.  Antimicrobial Peptides: New Recognition Molecules for Detecting Botulinum Toxins.

Authors:  Nadezhda V Kulagina; George P Anderson; Frances S Ligler; Kara M Shaffer; Chris Rowe Taitt
Journal:  Sensors (Basel)       Date:  2007-11-16       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.